Bioprocessing Analytics

Global Bioprocessing Analytics Market to Reach US$650.5 Million by 2030

The global market for Bioprocessing Analytics estimated at US$537.4 Million in the year 2024, is expected to reach US$650.5 Million by 2030, growing at a CAGR of 3.2% over the analysis period 2024-2030. Osmometers, one of the segments analyzed in the report, is expected to record a 2.6% CAGR and reach US$414.5 Million by the end of the analysis period. Growth in the Bioprocess Analyzers segment is estimated at 4.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$146.4 Million While China is Forecast to Grow at 5.9% CAGR

The Bioprocessing Analytics market in the U.S. is estimated at US$146.4 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$127.6 Million by the year 2030 trailing a CAGR of 5.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.8% CAGR.

Global Bioprocessing Analytics Market – Key Trends & Drivers Summarized

Why Is Bioprocessing Analytics Becoming Central to Biopharmaceutical Manufacturing?

The increasing complexity of biologic drugs and the high stakes associated with their production have made bioprocessing analytics a vital component in the biopharmaceutical manufacturing process. As biologics such as monoclonal antibodies, cell therapies, and gene therapies become more prominent, ensuring the consistency, safety, and efficacy of these products throughout the production lifecycle is imperative. Bioprocessing analytics involves real-time and offline monitoring of critical quality attributes and process parameters, allowing manufacturers to detect deviations, optimize yields, and maintain regulatory compliance. Traditional methods of quality testing, which relied heavily on post-production analysis, are giving way to integrated analytical tools that enable continuous monitoring and control throughout upstream and downstream processes. This shift aligns with the industry`s move toward Quality by Design (QbD) and Process Analytical Technology (PAT) frameworks advocated by regulatory agencies. Bioprocessing analytics helps reduce batch failures, minimize costs, and accelerate time to market by providing actionable insights at every stage of the production pipeline. The growing use of single-use technologies and continuous manufacturing further amplifies the need for robust analytics that can keep pace with dynamic production environments. As the global demand for biologics grows and therapies become more patient-specific, bioprocessing analytics will continue to serve as a cornerstone for achieving operational excellence and regulatory success in biomanufacturing.

How Are Technological Innovations Redefining the Scope and Accuracy of Bioprocessing Analytics?

Rapid advances in sensor technology, data analytics, machine learning, and automation are redefining how bioprocessing analytics are implemented and utilized in real-time manufacturing environments. Modern bioprocessing systems are now equipped with advanced inline and at-line sensors capable of continuously monitoring parameters such as pH, dissolved oxygen, temperature, turbidity, cell density, and metabolite concentrations with unprecedented precision. These sensors feed data into sophisticated control systems that allow for predictive adjustments, helping maintain optimal conditions and improve overall process stability. At the same time, machine learning algorithms and artificial intelligence are being employed to analyze vast datasets generated during production, enabling the early detection of anomalies and pattern recognition that would be impossible through manual oversight alone. Cloud-based platforms and integrated software suites are facilitating centralized data management, remote access, and cross-site comparisons, which are especially beneficial for multinational companies managing multiple facilities. Additionally, novel techniques such as Raman spectroscopy, near-infrared (NIR) spectroscopy, and mass spectrometry are being adapted for bioprocess monitoring, allowing for non-invasive and real-time measurements of complex biological mixtures. The ability to track these variables in real time not only ensures product quality but also reduces downtime and waste, creating a more sustainable manufacturing process. These technological innovations are enhancing both the granularity and accuracy of bioprocessing analytics, making them indispensable tools in the evolving landscape of biologics production.

What Market and Regulatory Trends Are Accelerating the Adoption of Bioprocessing Analytics Globally?

Global regulatory frameworks and market expectations are increasingly favoring the adoption of advanced bioprocessing analytics, prompting companies to integrate these systems into both existing and new production lines. Regulatory bodies such as the FDA, EMA, and PMDA have shifted their focus toward risk-based approaches and continuous monitoring, encouraging manufacturers to adopt Process Analytical Technology and Quality by Design principles. These frameworks require a deep understanding of process variability and critical quality attributes, which can only be achieved through robust analytical tools. In response, biopharmaceutical companies are proactively investing in analytics infrastructure to demonstrate compliance, de-risk their production pipelines, and secure faster regulatory approvals. On the market side, the growing complexity of biologics, including bispecific antibodies, antibody-drug conjugates, and personalized cell therapies, demands more granular process control and real-time feedback loops. Moreover, increased competition and pressure to reduce manufacturing costs are motivating manufacturers to minimize batch failures and improve yield efficiency through data-driven insights. The expanding footprint of contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) is also contributing to adoption, as these entities seek to standardize processes and differentiate through quality and consistency. In emerging economies, national initiatives to strengthen biopharmaceutical manufacturing capabilities are encouraging the deployment of modern analytics tools, often with support from public-private partnerships and international collaborations. These regulatory and market drivers are working in tandem to propel the widespread integration of bioprocessing analytics across regions and facility types.

What Are the Primary Growth Drivers Behind the Expansion of the Bioprocessing Analytics Market?

The growth in the bioprocessing analytics market is driven by a combination of industry evolution, technological capabilities, regulatory momentum, and strategic manufacturing shifts. One of the most powerful drivers is the rise of biologics in the global pharmaceutical market, including therapeutic proteins, monoclonal antibodies, and cell and gene therapies, all of which require stringent process control to ensure batch-to-batch consistency. The movement toward personalized medicine is further intensifying the need for real-time analytics, as smaller batch sizes and patient-specific therapies allow little room for error or rework. Technological innovation in sensors, software, and data analytics is enabling more granular, automated, and predictive control over complex bioprocesses, greatly enhancing efficiency and product quality. At the same time, regulatory agencies are reinforcing the need for integrated quality systems, encouraging manufacturers to invest in bioprocessing analytics to satisfy compliance requirements and reduce time to approval. The increasing adoption of continuous manufacturing and single-use bioreactors is also driving demand for in-line and on-line monitoring tools that can keep pace with fast-changing production dynamics. Additionally, the growing role of CMOs and CDMOs in drug development and production is fostering widespread standardization of analytical practices, further boosting demand. Economic pressures to reduce costs and maximize yields are prompting companies to adopt data-driven decision-making throughout their manufacturing operations. As global health demands continue to rise and biologic therapies become more central to modern medicine, the need for robust, real-time, and predictive bioprocessing analytics is expected to grow exponentially, driving expansion across both developed and emerging markets.

SCOPE OF STUDY:

The report analyzes the Bioprocessing Analytics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product (Osmometers, Bioprocess Analyzers); Application (Clinical Application, Industrial Application); End-User (Biopharmaceutical Companies End-User, Contract Research Organizations End-User, Contract Manufacturing Organizations End-User, Other End-Users)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• Agilent Technologies
• Applikon Biotechnology (Getinge)
• BlueSens gas sensor GmbH
• bbi-biotech GmbH
• Cytiva (Danaher Corporation)
• Endress+Hauser Group
• Eppendorf SE
• Hamilton Company
• Infors HT
• Kaiser Optical Systems Inc. (Endress+Hauser)
• Knauer Wissenschaftliche Geräte
• Merck KGaA (MilliporeSigma in US)
• Mettler-Toledo International
• Nova Biomedical Corporation
• Pall Corporation (Danaher)
• Parker Hannifin Corp. (SciLog)
• PreSens Precision Sensing GmbH
• Sartorius AG
• Thermo Fisher Scientific Inc.
• Waters Corporation

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.